Your browser doesn't support javascript.
loading
Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line.
Sakurai, Masatoshi; Okamoto, Shinichiro; Matsumura, Itaru; Murakami, Satsuki; Takizawa, Makiko; Waki, Masato; Hirano, Daiki; Watanabe-Nakaseko, Reiko; Kobayashi, Naoki; Iino, Masaki; Mitsui, Hideki; Ishikawa, Yuichi; Takahashi, Naoto; Kawaguchi, Tatsuya; Suzuki, Ritsuro; Yamamoto, Kazuhito; Kizaki, Masahiro; Ohnishi, Kazunori; Naoe, Tomoki; Akashi, Koichi.
Afiliação
  • Sakurai M; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. sakurai@z5.keio.jp.
  • Okamoto S; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
  • Matsumura I; Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
  • Murakami S; Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.
  • Takizawa M; Department of Hematology, Gunma University Hospital, Gunma, Japan.
  • Waki M; Department of Hematology, Kagawa Prefectural Central Hospital, Kagawa, Japan.
  • Hirano D; Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  • Watanabe-Nakaseko R; Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
  • Kobayashi N; Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
  • Iino M; Department of Hematology and Hematopoietic Stem Cell Transplantation, Yamanashi Prefectural Central Hospital, Yamanashi, Japan.
  • Mitsui H; Department of Hematology, Otemae Hospital, Osaka, Japan.
  • Ishikawa Y; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Takahashi N; Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
  • Kawaguchi T; Department of Medical Technology, Kumamoto Health Science University, Kumamoto, Japan.
  • Suzuki R; Department of Oncology and Hematology, Shimane University Hospital, Izumo, Japan.
  • Yamamoto K; Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.
  • Kizaki M; Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
  • Ohnishi K; Tokai-Hokuriku Block Blood Center, Seto, Japan.
  • Naoe T; Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  • Akashi K; Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan.
Int J Hematol ; 111(6): 812-825, 2020 Jun.
Article em En | MEDLINE | ID: mdl-32152876
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Tirosina Quinases / Leucemia Mieloide de Fase Crônica / Inibidores de Proteínas Quinases / Mesilato de Imatinib / Dasatinibe Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Tirosina Quinases / Leucemia Mieloide de Fase Crônica / Inibidores de Proteínas Quinases / Mesilato de Imatinib / Dasatinibe Idioma: En Ano de publicação: 2020 Tipo de documento: Article